Press releases
- Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
- Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress
- Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting
- Ryvu Therapeutics Summarizes 2023 Fiscal Year and Provides Corporate Update
- Ryvu Therapeutics Announces Disbursement of First Tranche of EUR 8 Million Venture Debt from the European Investment Bank
- Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting
More ▼
Key statistics
On Friday, Ryvu Therapeutics SA (9Y4:STU) closed at 12.16, 13.64% above the 52 week low of 10.70 set on May 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.06 |
---|---|
High | 12.36 |
Low | 12.06 |
Bid | 12.04 |
Offer | 13.44 |
Previous close | 12.06 |
Average volume | 0.00 |
---|---|
Shares outstanding | 23.12m |
Free float | 14.97m |
P/E (TTM) | -- |
Market cap | 1.25bn PLN |
EPS (TTM) | -4.10 PLN |
Data delayed at least 15 minutes, as of May 31 2024.
More ▼